Last 12.90 NOK
Change Today +0.10 / 0.78%
Volume 2.7K
PCIB On Other Exchanges
Symbol
Exchange
Berlin
As of 10:25 AM 03/3/15 All times are local (Market data is delayed by at least 15 minutes).

pci biotech holding asa (PCIB) Snapshot

Open
13.00 NOK
Previous Close
12.80 NOK
Day High
13.00 NOK
Day Low
12.80 NOK
52 Week High
03/19/14 - 31.63 NOK
52 Week Low
12/17/14 - 9.45 NOK
Market Cap
190.0M
Average Volume 10 Days
23.5K
EPS TTM
-3.99 NOK
Shares Outstanding
14.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PCI BIOTECH HOLDING ASA (PCIB)

Related News

No related news articles were found.

pci biotech holding asa (PCIB) Related Businessweek News

No Related Businessweek News Found

pci biotech holding asa (PCIB) Details

PCI Biotech Holding ASA, a cancer focused biopharmaceutical company, develops therapeutic products based on its proprietary photochemical internalisation (PCI) technology. The PCI technology induces triggered endosomal release and may be used to unlock the true therapeutic potential of various modalities, such as small molecules, ADCs, and siRNA. The company’s programs in clinical development include the photosensitizer Amphinex, which is in Phase II clinical trials for the treatment of head and neck cancer, as well as in Phase I/II clinical trials for the treatment of bile duct cancer. It is also developing PCI as a CTL induction technology for therapeutic and prophylactic vaccination. PCI Biotech Holding ASA was founded in 2000 and is headquartered in Lysaker, Norway.

Founded in 2000

pci biotech holding asa (PCIB) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: 1.6M NOK
Chief Financial Officer
Total Annual Compensation: 237.0K NOK
Compensation as of Fiscal Year 2013.

pci biotech holding asa (PCIB) Key Developments

PCI Biotech Holding ASA Reports Consolidated Earnings Results for the Fourth Quarter and Full Year December 31, 2014

PCI Biotech Holding ASA reported consolidated earnings results for the fourth quarter and full year December 31, 2014. For the quarter, the company reported other income of NOK 1.54 million compared to NOK 1.98 million a year ago. Operating loss was NOK 10.27 million compared to NOK 9.32 million a year ago. Ordinary loss before taxes was NOK 10.21 million compared to NOK 8.85 million a year ago. Net loss was NOK 10.21 million compared to NOK 8.85 million a year ago. Net cash flow used in operations was NOK 3.89 million compared to NOK 5.93 million a year ago. For the year, the company reported turnover of NOK 7.30 million compared to NOK 6.68 million a year ago. Operating loss was NOK 36.47 million compared to NOK 29.33 million a year ago. Ordinary loss before taxes was NOK 35.84 million compared to NOK 27.61 million a year ago. Net loss was NOK 35.84 million compared to NOK 27.61 million a year ago. Net cash flow used in operations was NOK 30.84 million compared to NOK 26.88 million a year ago.

PCI Biotech Holding ASA Announces Completion of the Third Group in the Intra-Tumour Light Dose Escalation Part of the Enhance Study

PCI Biotech Holding ASA reported that the treatment evaluation of the third group in the intra-tumour light dose escalation part of the ENHANCE study has been completed.- ENHANCE is a phase II study of Amphinex- in combination with the cytotoxic agent bleomycin in recurrent head and neck cancer patients. No safety concerns were raised and clear tumour responses with clinical benefits were seen at this light dose level. However, re-growth of tumour in the rim of the treatment area in some patients suggests a need to increase the treatment margins to achieve a durable disease response. A Dose Review Committee (DRC) of clinical experts and company representatives has been established to evaluate the results and provide recommendation for the continuation of the study. The DRC has recommended that an additional cohort of three patients is treated at the same light dose level, but with a modified treatment strategy extending the treatment margins. Patients for the next group are currently being screened and will be treated with Amphinex- as soon as possible.

PCI Biotech Receives Clearance by the United States Food and Drug Administration to Include Patients in the USA in Its Phase II Clinical Programme for Amphinex

PCI Biotech announced that it has received clearance by the United States Food and Drug Administration (FDA) to include patients in the USA in its phase II clinical programme for Amphinex. Amphinex is in development as a new local treatment for recurrent head and neck cancer and the phase II program has already been initiated in Europe.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PCIB:NO 12.90 NOK +0.10

PCIB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PCIB.
View Industry Companies
 

Industry Analysis

PCIB

Industry Average

Valuation PCIB Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 13.2x
Price/Book 20.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 22.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PCI BIOTECH HOLDING ASA, please visit www.pcibiotech.no. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.